What Molecule does

Molecule is a Switzerland-headquartered decentralized science (DeSci) platform, founded in 2021 and built primarily on Solana, that enables fractional ownership of early-stage biotech research through IP-NFT tokenization. The company operates a protocol and application stack connecting scientific researchers with aligned capital via community-governed DAOs and transparent on-chain funding structures, addressing what it characterizes as the "Valley of Death" funding gap between academic discovery and clinical development. Its core product is Labs — a unified platform that brings fundraising, collaboration, and real-time milestone tracking into a single interface — complemented by Discover (project browsing), Molecule Screener (early-stage research access), MIRA (an AI assistant), PeptAI (an autonomous peptide drug-discovery agent), and Science Beach (a March 2026 launch with Bio Protocol enabling AI agents and humans to co-develop scientific hypotheses).

The platform currently hosts an ecosystem of frontier DeSci DAOs including VitaDAO (17 projects, $4.1M deployed, with Pfizer's $500K investment representing mainstream pharma validation), Cerebrum DAO (7 projects, $947.79K deployed in brain health/Alzheimer's), HairDAO, PsyDAO, Athena DAO, ValleyDAO, and PeptAI, collectively spanning longevity, neurodegeneration, hair loss, psychedelics (with potential exposure to a $4.9M U.S. Department of Defense PTSD grant), women's health, synthetic biology, and peptide drug discovery. Molecule Protocol has connected 500+ institutions via tokenized pipelines. The company has raised approximately $27–28M across a 2020 pre-seed, a $12.7M seed led by Northpond Ventures in June 2022, a $7.5M Shine Capital-led extension in December 2022, and a $7M investment from a16z crypto in 2024.

Molecule monetizes through transaction fees on IP-NFT tokenization and commissions on biotech marketplace activity; pricing is not publicly disclosed. The go-to-market model is community-led, relying on developer relations, ecosystem partnerships within the DeSci movement, and word-of-mouth among hosted DAOs rather than traditional enterprise sales. The company employs 11–50 people and is led by CEO Paul Kohlhaas alongside a small C-suite (CCO, CLO, COO, CPO). No company-level revenue has been disclosed in the available data.

Name

Molecule

Legal name

Molecule

Website

https://molecule.to

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Molecule is a Switzerland-based decentralized science platform on Solana that enables fractional ownership of early-stage biotech research through IP-NFT tokenization, serving biotech researchers, DeSci funders, and patient-governed DAOs via its Labs platform and AI-driven products including PeptAI and Science Beach.

Ownership category

akta.pro rank

Product category

Decentralized Science Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Decentralized science platform
• Biotech research funding
• IP-NFT tokenization
• Biotech marketplace infrastructure
• DAO research governance

Headquarters

HQ city

Schaffhausen

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. NFT Tokenization Platform Fees: Molecule enables fractional ownership of drug candidates through NFT tokenization, generating revenue through platform fees from tokenization and trading of IP-NFTs on its biotech marketplace.
2. Biotech Marketplace: Platform facilitates transactions in biotech research assets, taking a commission or fee on trades and fundraises conducted through the marketplace infrastructure.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Molecule operates a blockchain-based decentralized science (DeSci) platform built on Solana that enables fractional ownership of biotech research through IP-NFT tokenization. The Labs platform brings funding, collaboration, and visible milestone tracking into a shared workspace, allowing biotech researchers to run streamlined fundraises while funders access early-stage, thesis-driven research with real-time capital and progress transparency. The platform supports a portfolio of frontier DeSci projects across longevity, brain health, peptide drug discovery, synthetic biology, and women's health, and includes AI-driven tools such as PeptAI for autonomous peptide discovery and Science Beach for collaborative hypothesis development.

Product overview

Molecule operates as a decentralized science (DeSci) platform built on Solana that combines aligned capital and shared infrastructure to make science more transparent, collaborative, and impactful. The core offering is Labs, a unified platform bringing funding, collaboration, and visible progress tracking together for scientific projects. Labs integrates with Discover for project browsing and Molecule Screener for accessing early-stage research. Molecule also offers PeptAI as an autonomous AI agent for peptide drug discovery, and Science Beach as an AI collaboration platform enabling scientists and AI agents to jointly develop hypotheses from initial ideas through IP funding. MIRA serves as the platform's AI assistant. The platform supports biotech DAOs and enables fractional ownership of drug candidates through NFT tokenization, with a compliance-ready structure providing a clear route to equity for funders.

Differentiator

Problem solved

Functional benefit

Products and services

• Labs Platform Shared platform that brings biotech research funding, collaboration, and visible milestone tracking into one workspace. Researchers launch streamlined fundraises and connect with biotech experts and patient communities; funders access early-stage, thesis-driven research with real-time capital and milestone visibility and a compliance-ready route to equity.
• PeptAI Autonomous AI agent for peptide drug discovery built on Molecule's ecosystem. Researchers specify a protein target and the agentic fleet sources candidate peptides, evaluates each against a multi-parameter screening cascade, and advances only qualifying candidates for lab validation.
• Science Beach Open scientific public domain on Solana enabling collaboration between AI agents and humans on scientific hypotheses from initial ideas through IP funding. Molecule provides an autonomous agent for research fee payments and result storage while Bio Protocol supplies the BIOS economic coordination layer.

Quantifiable outcome

• 500 institutions connected via tokenized pipelines
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core, flagship and minor.

• Bio ProtocolcoreStrategic or Co-development Partner · 6 March 2026Molecule on Solana and Bio Protocol launched Science Beach, an open scientific public domain enabling collaboration between AI agents and humans on scientific hypotheses from initial ideas through IP funding. Bio Protocol provides the BIOS economic coordination layer while Molecule deploys autonomous agents for research fee payments and result storage.
• VitaDAOflagshipStrategic or Co-development PartnerVitaDAO is a flagship longevity-focused DeSci project using Molecule's Labs platform with 17 projects funded and $4.1M deployed. VitaDAO received $500,000 investment from Pfizer, demonstrating mainstream validation of the DAO funding model.
• Cerebrum DAOcoreStrategic or Co-development PartnerCerebrum DAO is a brain health-focused DeSci project on Molecule's platform with 7 projects and $947.79K deployed, focused on tackling Alzheimer's disease.
• PeptAIcoreStrategic or Co-development PartnerPeptAI is an autonomous AI agent for peptide drug discovery built on Molecule's ecosystem. Researchers specify protein targets and the agentic fleet sources candidate peptides, evaluates against screening criteria, and advances qualifying candidates for lab validation.
• HairDAOminorStrategic or Co-development PartnerHairDAO is a DeSci project focused on hair loss research, part of the trusted frontier DeSci projects ecosystem on Molecule.
• PsyDAOcoreStrategic or Co-development PartnerPsyDAO is a psychedelic research DAO on Molecule's platform, positioned to benefit from a $4.9 million U.S. Department of Defense grant for psychedelic PTSD research.
• Athena DAOminorStrategic or Co-development PartnerAthena DAO is a women's health-focused DeSci project, part of the trusted frontier DeSci projects ecosystem on Molecule.
• ValleyDAOminorStrategic or Co-development PartnerValleyDAO is a synthetic biology-focused DeSci project, part of the trusted frontier DeSci projects ecosystem on Molecule.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Bio Protocol: DeSci launchpad and coordination layer that enables bioDAO formation and provides the BIOS economic coordination layer. Directly comparable as a DeSci infrastructure platform serving similar DAO-based research communities and biotech funding use cases.
• VitaDAO: Decentralized autonomous organization focused on longevity research, using Molecule's Labs platform for funding and project management. Functions both as a key customer and a peer demonstrating the DeSci funding model in production.
• Protocol Labs: Web3 infrastructure company behind IPFS and Filecoin, and an investor/strategic partner in Molecule's ecosystem. Provides decentralized storage and data infrastructure that underpins DeSci platforms, making it both an enabler and a comparable Web3-native science infrastructure company.

Broad incumbents

• Benchling: Leading cloud-based life sciences R&D platform serving hundreds of biotech and pharma companies with electronic lab notebooks, molecular biology tools, and registry capabilities. Broad incumbent in the biotech research software space that could expand into funding/collaboration features.
• LabArchives: Widely adopted electronic lab notebook (ELN) platform used by major research universities and institutions. Comparable as a research collaboration and documentation infrastructure layer, though focused on traditional institutional customers.
• Schrödinger: Physics-based computational chemistry platform providing molecular simulation and AI-driven drug design software to pharma companies globally. Broad incumbent offering overlapping AI/ML capabilities for molecular discovery.
• Recursion Pharmaceuticals: Clinical-stage biotech using AI and high-throughput experimentation to discover and develop medicines at scale. Broad incumbent in AI-driven drug discovery with significant capital and pipeline depth.
• TetraScience: Cloud-native data platform for life sciences R&D that centralizes and harmonizes lab data across enterprise pharma organizations. Broad incumbent in the biotech data infrastructure layer with potential to expand into research funding and collaboration workflows.

Emerging players

• Insitro: AI-driven drug discovery platform combining machine learning with high-throughput biology to advance therapeutic programs. Comparable as an AI-enabled approach to biotech R&D, though operating within a traditional venture-backed model rather than decentralized.
• Atomwise: AI-focused small molecule drug discovery company using deep learning for hit identification and lead optimization. Comparable as an AI platform enabling computational drug discovery, similar to Molecule's PeptAI peptide discovery agent.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Molecule_dao
• LinkedInlinkedin.com/company/molecule-protocol

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors37 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecule